A5020687901- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Cancer Diagnosis and Treatment
- Myasthenia Gravis and Thymoma
- Pituitary Gland Disorders and Treatments
- Radiation Dose and Imaging
- Advanced X-ray and CT Imaging
- Pleural and Pulmonary Diseases
- Cancer therapeutics and mechanisms
- Venous Thromboembolism Diagnosis and Management
- Congenital Diaphragmatic Hernia Studies
- Meningioma and schwannoma management
- Lymphoma Diagnosis and Treatment
- Endometrial and Cervical Cancer Treatments
- Advanced MRI Techniques and Applications
- Colorectal Cancer Treatments and Studies
- MRI in cancer diagnosis
- Vascular anomalies and interventions
- Kidney Stones and Urolithiasis Treatments
- Cholesterol and Lipid Metabolism
- Cannabis and Cannabinoid Research
- Lymphadenopathy Diagnosis and Analysis
Scientific Applications & Research Associates (United States)
2025
Memorial Sloan Kettering Cancer Center
2014-2023
Cornell University
2014-2022
Cancer Research And Biostatistics
2018
Translational Therapeutics (United States)
2011
Children's Hospital of Philadelphia
2011
University of Pennsylvania
2011
The Christie Hospital
1997-1998
To analyze long-term outcomes after treatment discontinuation of anti-programmed death-1 (anti-PD-1) therapy in a cohort patients with melanoma the longest follow-up yet available to our knowledge, including majority treated outside clinical trial. We also assessed efficacy retreatment anti-PD-1 or without ipilimumab relapsing patients.We retrospectively analyzed all nonuveal, unresectable stage III/IV single-agent at Memorial Sloan Kettering from 2009-2018 who had discontinued and least 3...
<h3>Importance</h3> The combination of erlotinib and bevacizumab as initial treatment epidermal growth factor receptor (<i>EGFR</i>[OMIM131550])–mutant lung cancers improves progression-free survival (PFS) compared with alone. Because osimertinib prolongs PFS erlotinib, this trial was designed to study the first-line treatment. <h3>Objectives</h3> To determine safety tolerability assess 12-month in patients metastatic<i>EGFR</i>-mutant cancers. <h3>Design, Setting, Particiants</h3> From...
Purpose To determine if there is added benefit of using iodine maps from dual-energy (DE) CT in addition to conventional angiography images diagnose pulmonary embolism (PE). Materials and Methods In this retrospective analysis, 1144 consecutive examinations performed January through September 2014 at an oncologic referral center evaluate for PE were reviewed. The included 1035 patients (mean age, 58.7 years; range, 15–99 years). First, the location, level, type (occlusive vs nonocclusive)...
BackgroundThymic carcinomas are rare cancers with limited data regarding outcomes, particularly for those patients advanced disease.MethodsWe identified thymic diagnosed between 1993 and 2012. Patient characteristics, recurrence-free survival (RFS), overall (OS) were analyzed.ResultsOne hundred twenty-one identified. Higher Masaoka stage was associated worse OS RFS (5-year of 100%, 81%, 51%, 24%, 17% I, II, III, IVa, IVb respectively, p < 0.001 5-year 80%, 28%, 7% I/II, IV 0.001). Patients...
The aim was to assess the performance of low-dose non-contrast CT urinary tract (LD-CT) acquired at radiation exposures close that abdominal radiography using adaptive statistical iterative reconstruction (ASiR).Thirty-three patients with clinically suspected renal colic were prospectively included. Conventional dose (CD-CT) and LD-CT data sets contemporaneously acquired. images reconstructed 40 %, 70 % 90 ASiR. Image quality subjectively objectively measured. Images also interpreted.Mean ED...
Background: Given the potential positive and negative impacts of cannabis use during cancer care, more information is needed to understand how changes in legalization social norms have affected clinical disclosure among survivors.Objectives: The purpose this research was explore behaviors, disclosure, needs survivors.Methods: study team conducted cross- sectional analyses using descriptive statistics assess data collected via an online survey distributed through health communities.Findings:...
BACKGROUND In a phase 1 study of pulse/continuous‐dose erlotinib, no patient had disease progression in the central nervous system (CNS). This expansion cohort tested same regimen individuals with epidermal growth factor receptor ( EGFR )–mutant lung cancers untreated brain metastases. METHODS Patients not received tyrosine kinase inhibitors or radiation for All 1200 mg erlotinib on days and 2 50 3 to 7 weekly. The primary endpoints were overall CNS response rates (according version 1.1...
Reverse cholesterol transport is the process by which excess removed from peripheral tissue HDL and delivered to liver for excretion. Presently, methods of measuring in vivo reverse do so monitoring appearance feces labeled that originated macrophage foam cells. These not account changes mass. We have developed an assay measure mass atherosclerotic cells.Macrophages are entrapped semipermeable (pore size 0.2 μm) hollow fibers surgically implanted into peritoneum recipient mice. The 24 hours...
9086 Background: Osimertinib (osi) demonstrated improved progression-free survival (PFS) over erlotinib as initial treatment (trmt) for EGFR-mutant (EGFR+) lung cancers. The addition of bevacizumab (bev) to trmt resulted in PFS compared alone (16 vs 10 months, HR 0.41). phase 1 study osi and bev confirmed the ability combine at full doses. Methods: 2 is assessing safety efficacy combination. primary endpoint 12 months; secondary endpoints include overall response (ORR), (OS), CNS PFS. All...
Inhibition of the MEK/ERK pathway is critical for Bcl-2-like protein 11 (BIM)-mediated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-induced apoptosis, and dysregulation this may be a mechanism acquired resistance. Therefore, MEK inhibition with trametinib an EGFR TKI resensitize tumors Limited targeted therapies are available after progression on TKIs, it in setting that we completed phase I/II study erlotinib trametinib.Patients metastatic EGFR-mutant lung...
Patients with EGFR-mutant lung cancer have no approved targeted therapies after disease progression on first-line osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Preclinical studies suggest that tumors both EGFR-sensitizing alteration and acquired second-site EGFR resistance alterations treatment osimertinib retain sensitivity to second-generation TKIs. We hypothesized dacomitinib, pan-human TKI, may be effective in this setting.In...
Objectives To assess outcomes and patterns of recurrence in patients with high-grade serous ovarian/tubal/primary peritoneal cancers radiographic supraclavicular lymphadenopathy at diagnosis. Methods We evaluated all newly diagnosed ovarian treated our center between January 1, 2008 May 2013 who had (defined as ≥1 cm short axis) on imaging (either computed tomography or positron emission tomography) the time Results Of 586 cancer receiving primary treatment during study period, we identified...